Department of Pathology, Stony Brook University Hospital, New York, NY 11794, USA.
Department of Laboratory Medicine, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Biomolecules. 2024 Jan 31;14(2):168. doi: 10.3390/biom14020168.
The percentage of tumor cells (tumor cellularity) in a cancerous tissue has been assumed to correlate with the variant allele fraction (VAF) of an identified pathogenic variant. Many laboratories use the tumor cellularity as part of a quality criteria for specimen processing and clinical reporting. However, a systematic study of such correlation has yet to be shown. We performed a relatively large-scale study to determine whether pathologist-estimated tumor cellularity is correlated with next-generation sequencing (NGS)-derived VAF. A total of 1511 non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) specimens, including formalin-fixed paraffin-embedded (FFPE) and fine needle aspirated (FNA) tissues, were analyzed by cancer hotspot NGS. For a given specimen, pathogenic variants of , , , and were identified and the determined VAFs were correlated with the corresponding tissue tumor cellularity. The coefficient of determination R-squared (R) values were calculated for each correlation. All R values were lower than 0.25, indicating poor correlations. Pathogenic variants were found, not uncommonly, in tumor specimens that carried 10% or lower tumor cellularity. There were no apparent differences of R values between the FFPE and FNA specimens. In both NSCLC and CRC, the lack of linear relationship between tumor cellularity and VAF was found across a wide range of tumor cell percentages. Caution should be used when using tumor cellularity to triage specimens for NGS testing. The tumor cellularity should be considered in relation to the limit of detection of the specific assay for the proper interpretation of a negative test result.
肿瘤组织中肿瘤细胞的百分比(肿瘤细胞密度)被认为与已确定的致病性变异的等位基因变异分数(VAF)相关。许多实验室将肿瘤细胞密度用作标本处理和临床报告的质量标准的一部分。然而,尚未对这种相关性进行系统研究。我们进行了一项相对大规模的研究,以确定病理学家估计的肿瘤细胞密度是否与下一代测序(NGS)衍生的 VAF 相关。总共分析了 1511 例非小细胞肺癌(NSCLC)和结直肠癌(CRC)标本,包括福尔马林固定石蜡包埋(FFPE)和细针穿刺(FNA)组织,通过癌症热点 NGS 进行分析。对于给定的标本,鉴定了 、 、 和 的致病性变体,并将确定的 VAF 与相应的组织肿瘤细胞密度相关联。为每个相关性计算了决定系数 R 平方(R)值。所有 R 值均低于 0.25,表明相关性较差。在肿瘤标本中,经常发现具有 10%或更低肿瘤细胞密度的致病性变体。FFPE 和 FNA 标本之间的 R 值没有明显差异。在 NSCLC 和 CRC 中,在广泛的肿瘤细胞百分比范围内,均发现肿瘤细胞密度与 VAF 之间不存在线性关系。在将肿瘤细胞密度用于对 NGS 检测进行标本分类时应谨慎。应根据特定检测的检测限来考虑肿瘤细胞密度,以正确解释阴性检测结果。